Arlene Tieng
Rheumatology · Bronx, NYNPI 1184872525
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (54.1%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Janssen Scientific Affairs, LLC at 43.8% of the total. Reporting peaked in 2022 at $17,069 and has fallen 57.1% since, to $7,315 in 2025. Among rheumatology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 402 payments — averaging $128.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Scientific Affairs, LLC$23K
- AbbVie$19K
- Amgen$4K
- Pfizer$3K
- UCB, Inc.$2K
- GSK$301
- plus $528 from 6 others
Across 3 payments — averaging $5882.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$18K
What the payments were for
- Consulting fees$27,85554%
- Speaking & faculty fees$11,62523%
- Travel & lodging$2,9416%
- Food & beverage$9,05318%
- Education$90%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Scientific Affairs, LLC | 4 | $22,560 |
| AbbVie | 28 | $19,176 |
| Amgen(2 entities) | 143 | $3,884 |
| Pfizer | 158 | $2,892 |
| UCB, Inc. | 31 | $2,142 |
| GSK | 13 | $301 |
| Lilly USA, LLC | 7 | $168 |
| Regeneron Healthcare Solutions, Inc. | 8 | $161 |
| Sanofi-aventis U.S. LLC | 3 | $75 |
| Bristol Myers Squibb | 3 | $52 |
| Sanofi | 3 | $49 |
| Novartis | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$51,483 in reported general payments places this provider in the 90th percentile of 541 rheumatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 202 | $1,583,548 |
| Enbrel SureclickEtanercept | 170 | $1,207,942 |
| RinvoqUpadacitinib | 80 | $474,977 |
| Enbrel MiniEtanercept | 59 | $412,907 |
| Xeljanz XrTofacitinib Citrate | 60 | $326,476 |
| Humira(Cf)Adalimumab | 36 | $234,747 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 26 | $191,138 |
| XeljanzTofacitinib Citrate | 32 | $174,487 |
| Cosentyx SyringeSecukinumab | 13 | $123,805 |
| EnbrelEtanercept | 16 | $113,280 |
| SimponiGolimumab | 19 | $108,078 |
| Humira PenAdalimumab | 12 | $77,753 |
| Taltz AutoinjectorIxekizumab | 12 | $77,676 |
| KevzaraSarilumab | 18 | $73,410 |
| OtezlaApremilast | 11 | $68,187 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira(Cf) | $19,176 | $709,725116 claims |
| AmgenEnbrel, Otezla | $3,884 | $181,46727 claims |
| PfizerXeljanz | $2,892 | $174,48732 claims |
| SanofiKevzara | $49 | $73,41018 claims |
| GSKBenlysta | $301 | $67,98715 claims |
| Lilly USA, LLCOlumiant | $168 | $61,76125 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 541 rheumatology providers in New York.
Other rheumatology in Bronx
- Vinita PatelBronx$73K
- Beverly JohnsonBronx$63K
- Laurie GlimcherNew York$3.9M
- Grace WrightNew York$3M
- Kostas BotsoglouCheektowaga$2.6M
- Sergio SchwartzmanNew York$2.5M
- Allan GibofskyNew York$1.9M
- Petros EfthimiouNew York$791K
- Richard FurieNew Hyde Park$746K
- Barry GruberBabylon$742K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.